Development of clinical researches on prevention aromatase inhibitor-associated bone loss by zoledronic acid

Abstract

Abstract: Aromatase inhibitors (AIs) are standard therpy for postmenopausal women with estrogen responsive breast cancers. By inhibiting the aromatase enzyme, causing decreases in endogenous estrogens, the treatment of AIs is responsible for lower bone mineral density (BMD) and increased fractures. Therefore, early recognition, prevention, and/or treatment of AI-induced bone loss is needed. Zoledronic acid is specific inhibitors of osteoclasts and extensively used in bone metastasis patients. Recently, there are several trials evaluating the use of intravenous zoledronic acid as prevention and treatment of AI-induced bone loss in postmenopausal women with breast cancer.In this article, we aim to review the use of zoledronic acid in this population including the response and safety.

Key words: Zoledronic acid, Aromatase inhibitors induce bone loss, Postmenopausal women with breast cancer

CLC Number:

WANG Zeng, WENG Lin, CHENG Bin. Development of clinical researches on prevention aromatase inhibitor-associated bone loss by zoledronic acid[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(4): 470-476.

References

[1] Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Statement Online 2000 March 27-29, 17(1): 1-36.
[2] Guo JH, Yao RB, Zhao ZM, et al. Analysis on influencing factor of effect for treating postmenopausal osteoporosis with risedronate sodium capsules[J]. Chin J Clin Pharmacol Ther, 2009,14(7):818-822.
[3] Lindsay R, Cosman F, Nieves J. Estrogen: effects and actions in osteoporosis[J]. Osteoporos Int, 1993,3(1):150-152.
[4] Eastell R, Hannon RA, Cuzick J, et al. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)[J]. J Bone Miner Res, 2006,21(8):1215-1223.
[5] Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17[J]. J Clin Oncol, 2006,24(22):3629-3635.
[6] Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or incombination trial 18233230[J]. J Clin Oncol, 2008,26(7):1051 -1057.
[7] Russell RG. Bisphosphonates: from bench to bedside[J]. Ann N Y Acad Sci, 2006,1068:367-401.
[8] Howell A, Cuzick J, Baum M, et al.As a part of the ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer[J]. Lancet, 2005,365(9453):60-62.
[9] Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer[J]. New Engl J Med, 2005,353(26):2747-2757.
[10] Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial[J]. Lancet, 2007, 369(9565):906.
[11] Jakesz R, Kaufmann M, Gnant M, et al. Switching of postmenoausal women with hormone sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3123 women enrolled in the ABCSG Trial 8 and ARNO 95 trial[J]. Lancet, 2005,366(9484):455-462.
[12] Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA 17[J]. J Natl Cancer Inst, 2005,97(17):1262-1271.
[13] Brufsky AM. Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors[J]. Clinical Breast Cancer, 2007,8(1):S22-S34.
[14] Gonnelli S, Cadirni A, Caffarelli C, et al. Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane[J]. Bone, 2007,40(1):205-210.
[15] Coates AS, Keshaviah A, Thürlimann B, et al. Five years of letrozole compared with tamoxifen as initial therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98[J]. J Clin Oncol, 2007,25(5):486-492.
[16] Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer[J]. J Clin Oncol, 2007,25(7):829 -836.
[17] Brufsky A. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update[J]. Semin Oncol, 2006,33(2 Suppl 7):S13-17.
[18] Brufsky A, Bundred N, Coleman R, et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole[J]. Oncologist, 2008,13(5):503-514.
[19] Brufsky A, Bosserman L, Caradonna R, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results[J]. Clin Breast Cancer, 2009,9(2):77-85.
[20] Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group[J].J Clin Oncol, 2007,25(7):820-828.
[21] Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole; ZO-FAST study results[J]. Cancer, 2008,112(5):1001-1010.
[22] Hines SL, Mincey B, Dentchev T, et al.Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC[J]. Breast Cancer Res Treat, 2009,117(3):603-609.
[23] Ryan CW, Huo D, Demers LM, et al. The Zometa US05 Investigators. Zoledronic acid initiated during the fi rst year of androgen-deprivation therapy increases bone mineral density in patients with prostate cancer patients[J]. J Urol, 2006,176(3):972-978.
[24] Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer[J]. J Urol, 2003,169(6):2008-2012.
[25] Tauchmanovà L, Ricci P, Serio B, et al. Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fi broblast progenitors after allogeneic stem cell transplantation[J]. J Clin Endocrinol Metab, 2005,90(2):627-634.
[26] Brown JE, Ellis SP, Lester JE, et al. Prolonged effi cacy of a single dose of the bisphosphonate zoledronic acid[J]. Clin Cancer Res, 2007,13(18 Pt 1):5406-5410.
[27] Reid DM, Doughty J, Eastell R, et al. Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group[J]. Cancer Treatment Reviews, 2008,34(Suppl 1):S3-S18.
[28] Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer[J]. J Clin Oncol, 2003,21(21):4042-4057.
[29] Bevers TB, Anderson BO, Bonaccio E. NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis[J]. J Natl Compr Canc Netw, 2009,7(10):1060-1096.